Hudert, C. A., Adams, L. A., Alisi, A., Anstee, Q. M., Crudele, A., Draijer, L. G., , , Furse, S., Hengstler, J. G., Jenkins, B., Karnebeek, K., Kelly, D. A., Koot, B. G., Koulman, A., Meierhofer, D., Melton, P. E., Mori, T. A., Snowden, S. G., van Mourik, I., Vreugdenhil, A., Wiegand, S., & Mann, J. P. (2022). variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17‐beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanisms. Hepatology communications, 6(8), 1934–1948. http://access.bl.uk/ark:/81055/vdc_100159763070.0x000005